Profile

Timothy S. Pardee, M.D., Ph.D.Wake Forest Baptist Health

Doctor Rating

4.8 out of 5

76 Ratings
9 Comments
 

Timothy S. Pardee, M.D., Ph.D.

Associate Professor,
Assistant Professor,

Clinical Interests

Acute and Chronic Leukemia, Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndromes, Hematologic Malignancies, Leukemia

Contact Information

Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Related Links

Education & Training

  • Ph.D., University of Buffalo - SUNY, 1999
  • M.D., University of Buffalo - SUNY, 2003
  • Residency, Internal Medicine, Massachusetts Gen Hosp, 2005
  • Fellowship, Hematology And Oncology, Stony Brook School of Medicine, 2009

Board Certifications

  • American Board of Internal Medicine, Hematology
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Medical Oncology

NPI Number

  • 1740386010
Timothy S. Pardee, M.D., Ph.D.

Doctor Rating

4.8 out of 5

76 Ratings
9 Comments
 

Timothy S. Pardee, M.D., Ph.D.

Associate Professor, Hematology & Oncology
Assistant Professor, Cancer Biology

Research Interests

Leukemia, Myeloid, Acute; Tumor Suppressor Protein p53; Antineoplastic Agents; DNA Topoisomerases, Type I; Thymidylate Synthase
More »

Contact Information

Academic: 336-745-0424 | Department: 336-716-4464

Related Links

Recent Publications

Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). Tawfik B, Pardee TS, Isom S, Sliesoraitis S, Winter A, Lawrence J, Powell BL, Klepin HD.. J Geriatr Oncol. 2016;7(1):24-31.

Improving nucleoside analogs via lipid conjugation: is fatter any better?. Alexander P, Kucera G, Pardee TS.. Crit Rev Oncol Hematol. 2016;100():46-56.

The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TS.. Future Oncol. 2016;12(17):2009-2020.

Effect of intensive chemotherapy on physical, cognitive, and emotional health of older adults with acute myeloid leukemia. Klepin HD, Tooze JA, Pardee TS, Ellis LR, Berenzon D, Mihalko SL, Danhauer SC, Rao AV, Wildes TM, Williamson JD, Powell BL, Kritchevsky SB.. J Am Geriatr Soc. 2016;64(10):1988-1995.

A phase II clinical trial of CPI-613 in patients with relapsed or refractory small cell lung carcinoma. Lycan TW, Pardee TS, Petty WJ, Bonomi M, Alistar A, Lamar ZS, Isom S, Chan MD, Miller AA, Ruiz J.. PLoS One. 2016;11(10):e0164244.

Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway. Gmeiner WH, Jennings-Gee J, Stuart CH, Pardee TS.. Leuk Res. 2015;39(2):229-235.

Clinicopathological analysis of near-tetraploidy/tetraploidy acute myeloid leukaemia. Pang CS, Pettenati MJ, Pardee TS.. J Clin Pathol. 2015;68(3):236-240.

High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Ahmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TS.. Leuk Res. 2015;39(9):945-949.

Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Howard DS, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.. J Clin Oncol. 2015;33(15 Suppl):7015.

The mitochondrial metabolism inhibitor Cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone is highly active in poor risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. Pardee T, Pladna K, Isom S, Ellis LR, Berenzon D, Howard D, Manuel M, Dralle S, Hurd DD, Lyerly S, Powell BL.. Blood. 2015;126(23):2556.

Feasibility of a symptom-adapted physical activity intervention during induction chemotherapy for older adults with acute myeloid leukemia (AML) [abstract]. Klepin HD, Tooze J, Pardee T, Ellis LR, Berenzon D, Howard D, Demark-Wahnefried W, Mihalko S, Rejeski WJ, Powell BL, Kritchevsky S.. Blood. 2015;126(23):2102.

Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T.. Ann Hematol. 2014;93(1):47-55.

The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells. Pardee TS, Stadelman K, Jennings-Gee J, Caudell DL, Gmeiner WH.. Oncotarget. 2014;5(12):4170-4179.

Acute myeloid leukemia and myelodysplastic syndromes in older adults. Klepin HD, Rao AV, Pardee TS.. J Clin Oncol. 2014;32(24):2541-2552.

The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, Kennedy L, Callahan KE, Klepin HD.. Leuk Res. 2014;38(10):1184-1190.

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.. Clin Cancer Res. 2014;20(20):5255-5264.

The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. Cook GJ, Caudell DL, Elford HL, Pardee TS.. PLoS One. 2014;9(11):e112619.

Adding KIT inhibitor dasatinib (DAS) to chemotherapy overcomes the negative impact of KIT mutation/over-expression in core binding factor (CBF) acute myeloid leukemia (AML): results from CALGB 10801 (alliance) [abstract]. Marcucci G, Geyer S, Zhao W, Caroll AJ, Bucci D, Uy GL, Blum W, Pardee T, Wetzler M, Stock W, Kolitz JE, Eisfeld AK, Bloomfield CD, Stone RM, Larson RA,.. Blood. 2014;124(21):8.

The mitochondrial metabolism inhibitor Cpi-613 is highly active in combination with high dose Ara-C (HiDAC) and mitoxantrone in a phase I study for relapsed or refractory acute myeloid leukemia (AML). Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Harrelson R, Manuel M, Dralle S, Lyerly S [sic] [Lyerly ES], Powell BL.. Blood. 2014;124(21):3744.

Non-homologous end joining mediated DNA repair is impaired in the NUP98-HOXD13 mouse model for myelodysplastic syndrome. Puthiyaveetil AG, Reilly CM, Pardee TS, Caudell DL.. Leuk Res. 2013;37(1):112-116.

Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity. Jennings-Gee J, Pardee TS, Gmeiner WH.. Exp Hematol. 2013;41(2):180-188.

Animal models of leukemia: any closer to the real thing?. Cook GJ, Pardee TS.. Cancer Metastasis Rev. 2013;32(1-2):63-76.

Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL.. Blood. 2013;121(21):4287-4294.

Near-tetraploid/tetraploid acute myeloid leukemia: morphologic, cytogenetic, and prognostic features [abstract]. Manny JS, Pardee T, Pettenati M, Pang CS.. Mod Pathol. 2012;25(Suppl 2):354A.

Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH.. Blood. 2012;119(15):3561-3570.

Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction. Pardee TS.. PLoS One. 2012;7(8):e43185.

The novel ribonucleotide reductase inhibitor didox is active against AML with limited toxicities [abstract]. Cook GJ, Caudell DL, Elford HL, Pardee T.. Blood. 2012;120(21):Abstr 1513.

Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. Pardee TS, Zuber J, Lowe SW.. Exp Hematol. 2011;39(4):473-485.

The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Ellis LR, Levitan D, Pardee TS, Isom S, Powell BL.. J Am Geriatr Soc. 2011;59(10):1837-1846.

Activity of the novel ribonucleotide reductase inhibitor didox on human and murine models of acute leukemia [abstract]. Cook GJ, Elford HL, Pardee T.. Blood. 2011;118(21):1553-1554.

Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP10 results in high efficacy against AML and low toxicity [abstract]. Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W.. Blood. 2011;118(21):1109-1110.

Altered lipid and mitochondrial metabolism are viable targets in acute leukemia [abstract]. Pardee T, DeFord-Watts LM, Peronto E, Levitan DA, Hurd DD, Kridel S.. Blood. 2011;118(21):1546.

Over expression of MN1 accelerates leukemia onset and confers resistance to chemotherapy by suppression of p53 and Bim [abstract]. Pardee T.. Blood. 2011;118(21):1070.

A single institution analysis of incidence of recurrent chromosomal abnormalities in adult ALL patients according to race, gender, and age [abstract]. Chiou V, Tiegs J, Isom S, Pettenati MJ, Lyerly S, Ellis LR, Pardee T, Dmitriy B, Powell BL, Levitan DA.. Blood. 2011;118(21):4869.

Geriatric assessment predicts overall survival among older adults receiving induction chemotherapy for acute myelogenous leukemia [abstract]. Klepin HD, Tooze JA, Geiger AM, Kritchevsky S, Williamson J, Ellis LR, Levitan D, Pardee T, Isom S, Powell BL.. Blood. 2010;116(21):653-654.

Over expression of MN1 confers resistance to chemotherapy in vitro and in vivo [abstract]. Pardee T, Mascenik T, Bolemon BH, Cook GJ.. Blood. 2010;116(21):427.

The novel fluoropyrimidine FdUMP[10] is highly active against acute myeloid leukemia [abstract]. Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W.. Blood. 2010;116(21):1353.

The FLT3 ITD accelerates an already established myeloid leukemia and alters chemotherapy response in vitro and in vivo in a p53 dependent manner [abstract]. Pardee T, Zuber J, Lowe S.. Blood. 2009;114(22):685.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Hematology & Oncology

Clinical Interests

Acute and Chronic Leukemia, Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndromes, Hematologic Malignancies, Leukemia
Timothy S. Pardee, M.D., Ph.D.

Timothy S. Pardee, M.D., Ph.D.

Associate Professor, Hematology & Oncology
Cancer Biology

Doctor Rating

4.8 out of 5

Timothy S. Pardee, M.D., Ph.D.76 Ratings
9 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.9
CP efforts to include in decisions
4.8
CP explanations of prob/condition
4.9
CP spoke using clear language
4.9
Friendliness/courtesy of CP
4.9
Likelihood of recommending CP
4.9
Patients' confidence in CP
4.9
Time CP spent with patient
4.8
Wait time at clinic
3.7



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

10/4/2016

Nothing to complain about.

8/1/2016

I wouldn't be have today if it wasn't for *Dr. Pardee & staff.

7/18/2016

*Dr. Pardee is one of the best providers I have ever been involved with.

5/17/2016

I am exceptionally impressed and please with the doctor & the care I received!

2/17/2016

*Dr. Pardee & assistant, *Lauren Imboden, are both good caregivers. They genuinely seem to care for me.

2/17/2016

*Dr. PA & nurses were all so wonderful. They didn't talk in language we couldn't understand - very informative.

1/28/2016

All good.

1/10/2016

All good

1/7/2016

*Dr. Pardee is one of the best physicians I have ever been involved with.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.